



**CLINICAL UPDATES ON  
ACUTE LEUKEMIAS**

Budapest, Hungary

May 4-6, 2018

Chairs : Hervé Dombret, Arnold Ganser, Jorge Sierra, Wendy Stock

**Friday, May 4<sup>th</sup>, 2018**

**SESSION I – Case-based lectures on diagnosis & prognosis**

**Chairs: Robin Foa (Rome), Torsten Haferlach (Munich)**

14:00-14:20	Diagnosis of BCR-ABL1-like ALL	Charles Mullighan (Memphis)
14:20-14:25	<i>Discussion</i>	
14:25-14:45	Bad-prognostic factors in ALL	Nicolas Boissel (Paris)
14:45-14:50	<i>Discussion</i>	
14:50-15:10	ALL diagnosis and classification	Torsten Haferlach (Munich)
15:10-15:15	<i>Discussion</i>	
15:15-15:35	Measurable residual disease in AML	Gert Ossenkoppele (Amsterdam)
15:35-15:40	<i>Discussion</i>	
15:40-16:00	<i>Panel discussion</i>	
<b>16:00-16:20</b>	<b><i>Coffee break</i></b>	
16:20-17:20	<b>ROUNDTABLE I – The origin of leukemic cells</b>	
	<b>Chairs: Charles Mullighan (Memphis), Torsten Haferlach (Munich)</b>	
16:20-16:45	The AML - T-ALL frontier	Elizabeth Macintyre (Paris)
16:45-16:50	<i>Discussion</i>	
16:50-17:15	The leukemic stem cells	TBA
17:15-17:20	<i>Discussion</i>	
17:20-18:20	<b>DEBATE – Is transplant needed to cure Ph+ ALL in patients who achieve MRD negativity?</b>	
	<b>Chairs: Wendy Stock (Chicago), Hervé Dombret (Paris)</b>	
17:20-17:40	Yes	Oliver Ottmann (Cardiff)
17:40-17:45	<i>Discussion</i>	
17:45-18:05	No	Farhad Ravandi (Houston)
18:05-18:10	<i>Discussion</i>	
18:10-18:30	<b>INTERACTIVE CASE 1</b>	

**18:45-20:15**     **Slot for a satellite symposium**

**20:15-21:30**     **Get together and poster viewing (stand up cocktails and buffet dinner for all)**

**Saturday, May 5<sup>th</sup>, 2018**

**07:50-08:50**     **3 Simultaneous breakfast meet the expert sessions**

**SESSION II – Case-based lectures on standard AML therapy**  
**Chairs: Nigel Russel (Nottingham), Christoph Röllig (Dresden)**

09:00-09:15	How to use “standard” chemotherapy?	Bob Löwenberg (Rotterdam)
09:15-09:20	<i>Discussion</i>	
09:20-09:35	Treatment of good ELN risk AML	Jorge Sierra (Barcelona)
09:35-09:40	<i>Discussion</i>	
09:40-09:55	Treatment of poor ELN risk AML	Richard Schlenk (Heidelberg)
09:55-10:00	<i>Discussion</i>	
10:00-10:15	Salvage therapy	Arnold Ganser (Hannover)
10:15-10:20	<i>Discussion</i>	
10:20-10:40	<i>Panel discussion</i>	

**10:40-11:10**     ***Coffee break***

**SESSION III – Case-based lectures on targeted & other therapy in AML**  
**Chairs: Richard Schlenk (Heidelberg), Fährad Ravandi (Houston)**

11:10-11:25	FLT3 inhibitors	Mark Levis (Baltimore)
11:25-11:30	<i>Discussion</i>	
11:30-11:45	IDH inhibitors	Martin Tallman (New York)
11:45-11:50	<i>Discussion</i>	
11:50-12:05	Arsenic & ATRA in APL	Pierre Fenaux (Paris)
12:05-12:10	<i>Discussion</i>	
12:10-12:25	Nucleoside analogs	Nigel Russel (Nottingham)
12:25-12:30	<i>Discussion</i>	
12:30-12:45	Gemtuzumab Ozogamicin	Alan Burnett (Isle of Arran)
12:45-12:50	<i>Discussion</i>	
12:50-13:10	<i>Panel discussion</i>	

**13:10-14:15**     ***Lunch***

**14:15-14:55**     **ROUNDTABLE II – A revival for maintenance therapy in AML?**  
**Chairs: Bob Löwenberg (Rotterdam), Andrew Wei (Melbourne)**

14:15-14:30	Maintenance therapy with targeted agents	Christoph Röllig (Dresden)
14:30-14:35	<i>Discussion</i>	

14:35-14:50 Maintenance therapy after transplantation Charles Craddock (Birmingham)  
14:50-14:55 Discussion

**SESSION IV – Case-based lectures on older patients with AML**  
**Chairs: Jorge Sierra (Barcelona), Alan Burnett (Isle of Arran)**

14:55-15:10 Low-intensity treatments Hervé Dombret (Paris)  
15:10-15:15 Discussion

15:15-15:30 Adding new drugs to low-intensity treatments Gail Roboz (New York)  
15:30-15:35 Discussion

15:35-15:50 Targeting cell survival in AML Andrew Wei (Melbourne)  
15:50-15:55 Discussion

15:55-16:10 Transplant in older adults Fred Appelbaum (Seattle)  
16:10-16:15 Discussion

16:15-16:35 Panel discussion

**16:35-16:55 Coffee break**

16:55-17:15 **INTERACTIVE CASE 2**

17:15-17:35 **ROUNDTABLE 3 – A role for immunotherapy in AML?**  
**Chairs: Gert Ossenkoppele (Amsterdam), Martin Tallman (New York)**

17:15-17:30 Target antigens Marion Subklewe (Munich)  
17:30-17:35 Discussion

**17:50-19:20 Slot for a satellite symposium**

**Sunday, May 6, 2018**

**08:00-08:50 3 Simultaneous breakfast meet the expert sessions**

**SESSION V – Case-based lectures on targeted & immunotherapies in ALL**  
**Chairs: Oliver Ottmann (Cardiff), Nicolas Boissel (Paris)**

09:00-09:15 TKI in Ph+ & Ph-like Robin Foa (Rome)  
09:15-09:20 Discussion

09:20-09:35 Antibodies & ADCs Wendy Stock (Chicago)  
09:35-09:40 Discussion

09:40-09:55 BiTEs Nicola Gökbuget (Frankfurt)  
09:55-10:00 Discussion

10:00-10:15 CAR T-cells Noelle Frey (Philadelphia)  
10:15-10:20 Discussion

10:20-10:40 Panel discussion

**10:40-11:00**     *Coffee break*

11:00-11:15     Resistance to new immunotherapy

Jae Park (New York)

11:15-11:20     *Discussion*

11:20-11:45     Where are we going?

Bob Löwenberg (Rotterdam)

11:45-11:50     *Discussion*

**11:50-12:00**     *Closing remarks*

**MEETING CLOSURE**

*\*Pending confirmation*